Table of Content
- Introduction
- Definition of Neuroendocrine Tumor Treatment Market
- Scope of the Report
- Methodology
- Executive Summary
- Market Overview
- Market Definition and Segmentation
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porter's Five Forces Analysis
- PESTEL Analysis
- Neuroendocrine Tumor Treatment Market, By Treatment Type:
- Surgery
- Chemotherapy
- Targeted Therapy
- Peptide Receptor Radionuclide Therapy (PRRT)
- Neuroendocrine Tumor Treatment Market, By Tumor Site:
- Lung Neuroendocrine Tumors (NETs)
- Pancreatic Neuroendocrine Tumors (NETs)
- Gastrointestinal Neuroendocrine Tumors (NETs)
- Others
- Neuroendocrine Tumor Treatment Market, By End-User:
- Hospitals
- Specialty Clinics
- Research Institutes
- Neuroendocrine Tumor Treatment Market,, By Geography
- North America
- United States
- Canada
- Europe
- United Kingdom
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of Middle East & Africa
- North America
- Competitive Landscape
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio and Description
- Key Highlights
- Financial Overview
- Ipsen Pharma
- Pfizer Inc.
- Advanced Accelerator Applications (a subsidiary of Novartis)
- Progenics Pharmaceuticals (a subsidiary of Lantheus Holdings, Inc.)
- Roche Holding AG
- Amgen Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company)
- Dauntless Pharmaceuticals
- Delcath Systems, Inc.
- Genentech, Inc. (a subsidiary of Roche Holding AG)
- ItMatters, Inc.
- Novartis AG
- Conclusion and Future Outlook
- Appendix
- Research Methodology
- About the Pharmanucleus
- Disclaimer